D4-Pharma SRL
10.5 FTEThe score of D4-Pharma shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity -29 % Total assets +80 % Headcount (avg FTE) -14 %
Accounts of the company itself (not consolidated).
The full file covers 9 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
D4-Pharma's annual accounts
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net result | 15,203 € | ||||
| Equity | 167,820 € | ||||
| Cash | 122,742 € | ||||
| EBITDA | 129,146 € | ||||
| Total assets | €1.77m |
Filed annual accounts
- Year ended 31 Dec 2025filed on 31 Aug 2026
- Year ended 31 Dec 2024filed on 28 Aug 2025
- Year ended 31 Dec 2023filed on 30 Aug 2024
- Year ended 31 Dec 2022filed on 14 Sep 2023
- Year ended 31 Dec 2021filed on 17 Oct 2022
D4-Pharma's financial analysis
- Solvency9.5%sector median: 37.8%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of D4-Pharma
D4-Pharma's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0670.945.535
- VAT number
- BE0670945535
- Peppol
- Registered · 0208:0670945535 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 10 Feb 2017
- Registered office
- 1040 Etterbeek
- Size
- Small · 10.5 FTE
- Latest accounts
- 2025 · filed on 31 Aug 2026
- Activity
- Retail sale of pharmaceutical products (NACE 47730)
D4-Pharma (SRL) has been based in Etterbeek since 2017, active in: retail sale of pharmaceutical products. For 2025, it reports a net profit of 15,203 € and equity of 167,820 €; its revenue is not published. With 10.5 full-time equivalents, it is a small enterprise by headcount. Its solvency stands at 9.5%, below the median of its sector (37.8%).
Companies similar to D4-Pharma
Companies in the same business, of comparable size and area, outside its group.
- Inge Thoelen Retail sale of pharmaceutical products Landen · balance sheet €1.74m
- Apotheek Orbie Retail sale of pharmaceutical products Middelkerke · balance sheet €1.77m
- Pharmacie Gosselin-Obourg Retail sale of pharmaceutical products Mons · balance sheet €1.77m
- Farmagora Retail sale of pharmaceutical products Ternat · balance sheet €1.78m
- Phargest Retail sale of pharmaceutical products Profondeville · balance sheet €1.78m
- Selvais Retail sale of pharmaceutical products Bastogne · balance sheet €1.75m
- Hampharma Retail sale of pharmaceutical products Tessenderlo-Ham · balance sheet €1.75m
- Bytebier Kaatje Retail sale of pharmaceutical products Boechout · balance sheet €1.80m
Frequently asked questions about D4-Pharma
What is the revenue of D4-Pharma?
D4-Pharma files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of D4-Pharma?
In Belgium, the VAT number is the company number prefixed with BE: BE0670945535 for D4-Pharma, if the company is VAT-registered. Its company number (CBE) is 0670.945.535.
Where is the registered office of D4-Pharma?
According to the CBE register, the registered office of D4-Pharma is in 1040 Etterbeek.
What is the equity of D4-Pharma?
At the close of the 2025 financial year, the equity of D4-Pharma amounts to 167,820 €, a solvency of 9.5% of total assets.
How many people work at D4-Pharma?
10.5 full-time equivalents on average according to the 2025 social balance sheet.
Who manages D4-Pharma?
The register lists 2 active mandates at D4-Pharma. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of D4-Pharma
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →